TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that new preclinical data relating to the use of its oncolytic immunotherapy platform
Eteläuomen Läi Akseli Hemminki Kostenloser Wertpapierhandel Aino Kalervo Scius Communications University Of Helsinki Finland
Source: finanznachrichten.de